Notícias e Atividades da AIM ImmunoTech
Executivos
Veja o organograma con seus 9 executivos principais
Biografias mais buscadas da AIM ImmunoTech
- Thomas Equels, Executive Vice Chairman, Chief Executive Officer an...
- Stewart Appelrouth, Director
- William Mitchell, Chairman of the Board
Recentes movimentos de executivos em AIM ImmunoTech
- David Chemerow, ingressou na Companhia como Independent Director (Notícia publicada em 27 de fevereiro de 2025).
Criar um alerta
para seguir os movimentos de executivos da AIM ImmunoTech.
Biotecnologia
AIM ImmunoTech possui 2.351 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de AIM ImmunoTech
- Press Releases | AIM Immunotech
- AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - AIM ImmunoTech Inc.
- AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
- AIM ImmunoTech Issues Letter to Stockholders - AIM ImmunoTech Inc.
- AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - AIM ImmunoTech Inc.
- AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?" - AIM ImmunoTech Inc.
- AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - AIM ImmunoTech Inc.
- AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - AIM ImmunoTech Inc.
- View more press releases Close
Redes sociais sobre AIM ImmunoTech
- AIM ImmunoTech na Wikipedia, Google News e Yahoo Finance
- AIM ImmunoTech na LinkedIn, Twitter e YouTube
